gammanorm 165 mg/ml roztwór do wstrzykiwań
octapharma (ip) sprl - immunoglobulinum humanum normale - roztwór do wstrzykiwań - 165 mg/ml
myfortic 180 mg tabletki dojelitowe
novartis poland sp. z o.o. - acidum mycophenolicum - tabletki dojelitowe - 180 mg
marelim 360 mg tabletki dojelitowe
accord healthcare polska sp. z o.o. - acidum mycophenolicum - tabletki dojelitowe - 360 mg
cuvitru 200 mg/ml roztwór do wstrzykiwań
takeda pharma sp. z o.o. - immunoglobulina ludzka normalna - roztwór do wstrzykiwań - 200 mg/ml
marelim 180 mg tabletki dojelitowe
accord healthcare polska sp. z o.o. - acidum mycophenolicum - tabletki dojelitowe - 180 mg
mycofit 500 mg tabletki powlekane
accord healthcare polska sp. z o.o. - mycophenolas mofetil - tabletki powlekane - 500 mg
yescarta
kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - Środki przeciwnowotworowe - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.
mycofit 250 mg kapsułki twarde
accord healthcare polska sp. z o.o. - mycophenolas mofetil - kapsułki twarde - 250 mg
mykofenolan mofetylu accord 500 mg proszek do sporządzania koncentratu roztworu do infuzji
accord healthcare polska sp. z o.o. - mycophenolas mofetil - proszek do sporządzania koncentratu roztworu do infuzji - 500 mg
idefirix
hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - leki immunosupresyjne - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.